Sarepta Therapeutics’ (SRPT) “Buy” Rating Reiterated at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a report released on Thursday, Benzinga reports. They presently have a $166.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price objective would indicate a potential upside of 26.81% from the stock’s previous close.

Other research analysts also recently issued reports about the stock. Cantor Fitzgerald restated a “neutral” rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Mizuho upped their price target on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. BMO Capital Markets initiated coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 price target for the company. Barclays upped their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Finally, Royal Bank of Canada upped their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $156.60.

Sarepta Therapeutics Stock Up 3.3 %

Shares of SRPT opened at $130.90 on Thursday. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $159.89. The company has a market cap of $12.37 billion, a P/E ratio of -21.39 and a beta of 0.95. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.95 and a quick ratio of 3.45. The firm has a 50 day simple moving average of $125.80 and a two-hundred day simple moving average of $110.42.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. During the same period in the previous year, the business earned ($1.44) earnings per share. The company’s revenue was up 63.1% on a year-over-year basis. Research analysts forecast that Sarepta Therapeutics will post 2.13 EPS for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the sale, the director now owns 7,516 shares of the company’s stock, valued at $923,941.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Ian Michael Estepan sold 1,200 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The disclosure for this sale can be found here. Insiders have sold a total of 22,096 shares of company stock valued at $2,739,419 over the last 90 days. 7.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. Principal Securities Inc. bought a new position in shares of Sarepta Therapeutics during the 4th quarter worth about $26,000. Mather Group LLC. purchased a new stake in Sarepta Therapeutics in the 1st quarter valued at about $28,000. Montag A & Associates Inc. purchased a new stake in Sarepta Therapeutics in the 3rd quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC increased its stake in Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 154 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 87 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.